Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study
Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...
Saved in:
| Main Authors: | Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Urological Oncology Society
2024-03-01
|
| Series: | Journal of Urologic Oncology |
| Subjects: | |
| Online Access: | http://www.e-juo.org/upload/pdf/juo-234600660033.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma
by: Shengyuan Xu, et al.
Published: (2025-05-01) -
Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Hengyu Tian, et al.
Published: (2025-04-01) -
Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases
by: Vanda Salutari
Published: (2025-06-01) -
Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
by: Junfeng Bu, et al.
Published: (2025-02-01) -
Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
by: Shasha Sun, et al.
Published: (2024-12-01)